Clinical Trials on Preleukemia in Taiwan

Total 19 results

Johnson & Johnson Taiwan Ltd

Completed

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Taiwan
Celgene

Completed

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Taiwan
National Taiwan University Hospital

Recruiting

Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Aplastic Anemia | Myeloproliferative Neoplasm

Taiwan
TJ Biopharma Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes(MDS)

China
Millennium Pharmaceuticals, Inc.

Completed

A Study of Pevonedistat in Adult East Asian Participants

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan, Taiwan, Korea, Republic of
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
Hemavant Sciences GmbH

Terminated

A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes (Encore-MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

Korea, Republic of, United States, Taiwan, Belgium, France, Spain, Italy
Novartis Pharmaceuticals

Active, not recruiting

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1)

Myelodysplastic Syndromes

Czechia, Hungary, Japan, Taiwan, United States, Belgium, Italy, United Kingdom, Korea, Republic of, Hong Kong, Austria, Germany, Turkey, Spain, Greece, France, Canada
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes (PROMYS)

Myelodysplastic Syndromes | Adult

Belgium, United States, Austria, United Kingdom, Italy, Taiwan, Brazil, China, Croatia, Czechia, France, Germany
AbbVie
Genentech, Inc.

Active, not recruiting

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

Myelodysplastic Syndrome (MDS)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Hungary
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Novartis Pharmaceuticals

Completed

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (ASPIRE)

Thrombocytopaenia

United States, Belgium, Canada, Hong Kong, Argentina, Brazil, Czechia, Germany, Greece, Israel, Netherlands, Spain, Thailand, Hungary, Ireland, Italy, Mexico, Taiwan, Korea, Republic of, Poland, Russian Federation, Puerto Rico
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
GlaxoSmithKline

Completed

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Myelodysplastic Syndrome

Puerto Rico, United States, Taiwan, Germany, Denmark, Hong Kong, Korea, Republic of, France, United Kingdom, Italy, Brazil
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasms (MPNs)

United States, Spain, Korea, Republic of, France, Taiwan, Australia, Belgium, Singapore, Israel, Canada, Germany, Finland
Celgene

Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Beta-thalassemia | Myelodysplastic Syndromes (MDS) | Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

United States, Japan, United Kingdom, Turkey, Greece, France, Australia, Belgium, Bulgaria, Canada, Germany, Israel, Italy, Malaysia, Spain, Sweden, Taiwan, Thailand, Tunisia, Lebanon, China, Netherlands

Clinical Trials on Preleukemia in Taiwan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations